How Long After Hep B Vaccine to Get Titer?

A titer check after hepatitis B vaccination should be drawn one to two months after your final dose. That window gives your immune system enough time to mount a full antibody response while keeping the result high enough to read clearly. In a large cohort study, testing at one to two months produced a seroprotection rate of about 98%, while waiting longer led to noticeably lower numbers on paper, not because protection had actually failed but because antibody levels naturally begin to settle after their peak. The timing matters more than most people realize, and testing too early or too late can each create problems of their own.

Why One to Two Months Is the Recommended Window

After the last dose of a standard three-dose hepatitis B series, your body ramps up production of antibodies against the hepatitis B surface antigen. Those antibodies peak roughly four to eight weeks out, which is why guidelines from the CDC and most infectious-disease authorities point to one to two months as the ideal testing window. A study of a large cohort of healthy adults found that seroprotection measured at one to two months after the final dose was 98.2%. Testing earlier than one month showed a slightly lower rate of 97.3%, a difference that was not statistically meaningful but still suggests antibodies had not quite peaked. Far more striking was what happened when testing was delayed: at three to six months the rate dropped to 90.6%, and at seven months or more it fell to 88.4%.¹

Those declines do not necessarily mean people lost their immunity. Antibody levels naturally drop after the peak, even in healthy people who are fully protected. But the titer test only measures what is circulating in your blood at that moment. If you wait six months and your level falls below the protective threshold, you could be told you need revaccination when your immune system would actually fight off the virus just fine. Testing in that one-to-two-month window avoids this false alarm.

What the Test Measures and What Counts as Protective

The blood test ordered after vaccination is called a quantitative anti-HBs (hepatitis B surface antibody) test. It measures how many antibody units you have per milliliter of blood, reported as mIU/mL. The universally accepted cutoff for seroprotection is 10 mIU/mL. If your result is at or above that level, you are considered immune. In a study of healthcare workers in South India, about 92.5% tested as seroprotected, with nearly 79% showing high titers above 100 mIU/mL and roughly 14% falling in the moderate range of 10 to 100 mIU/mL.²

The distinction between a titer of, say, 15 and one of 500 matters less than you might think for day-to-day protection. Both readings confirm you responded to the vaccine. However, a higher peak titer after vaccination tends to predict that detectable antibodies will stick around longer before falling below 10. People who peaked in the moderate range are more likely to drop below the threshold within a few years, even though they still retain immune memory that can kick in if they encounter the virus.

A Different Timeline for Infants Born to Hepatitis B-Positive Mothers

If a baby is born to a mother who carries hepatitis B, the infant receives both the vaccine and hepatitis B immune globulin (HBIG) at birth. The testing schedule for these babies is quite different from the adult timeline. Rather than checking one to two months after the last dose, guidelines recommend testing these infants between 9 and 15 months of age.³

The reason for the delay is practical. Infants receive HBIG at birth, and that passive antibody can linger in the bloodstream for months. If you tested too early, the antibodies you measured might be from the injection the baby received at birth rather than antibodies the baby’s own immune system manufactured. By waiting until at least nine months, you can be confident that the HBIG has cleared and any anti-HBs detected is the baby’s own immune response. The test at this age also checks for hepatitis B surface antigen, confirming the infant was not infected despite the exposure.

Dialysis and Immunocompromised Patients Face Steeper Odds

People on hemodialysis have a notoriously harder time responding to the hepatitis B vaccine. Their immune systems are suppressed by kidney failure itself, and the response rates are far lower than in healthy adults. In one study of dialysis patients, 41% never reached the protective threshold of 10 mIU/mL at all, while about 22% were “poor responders” with titers between 10 and 100, and only 37% achieved titers above 100.⁴ Making matters worse, more than half of the poor responders dropped back below protective levels within a year of follow-up.

For dialysis patients, the testing window remains one to two months after the last dose, but the clinical significance is different. Because response rates are lower and titers fade faster, many dialysis centers recheck titers annually and give booster doses when levels fall below 10. The standard three-dose series is often given at double the usual dose for this group, and some centers now use a newer adjuvanted vaccine that has shown higher seroprotection rates in this population. A real-world comparison of conventional and adjuvanted vaccines in dialysis patients found that seroprotection was achieved at higher rates and more quickly with the adjuvanted formulation.⁵

Other groups with blunted immune responses include people living with HIV, organ transplant recipients on anti-rejection medications, and those undergoing chemotherapy. The same general approach applies: check the titer one to two months after the final dose, and expect a higher chance of needing revaccination or boosters.

What If Your Titer Comes Back Below 10?

A result below 10 mIU/mL after a complete vaccine series means you did not mount a measurable protective response. The usual next step is to receive another full three-dose series and retest one to two months after that final dose. Most people who failed the first series will respond to a second one. If you still show no response after six total doses, you are classified as a non-responder.

There is some nuance here. Research suggests that people whose titers land just below 10, particularly between 2 and 10, often still have some degree of immune memory that could activate on exposure. One group of researchers concluded that a booster dose or repeat series should primarily be suggested for people whose anti-HBs level falls below 2, or for those who experience a needlestick or other direct exposure to contaminated blood.⁶ Still, in practical clinical terms, most occupational health programs in hospitals treat any result below 10 as a prompt for revaccination.

Why Some People Never Respond

Somewhere between 5% and 10% of healthy adults fail to develop protective antibodies after a standard hepatitis B vaccine series. The reasons are varied and not entirely within your control. A scoping review of non-response identified several consistent risk factors: older age, obesity, smoking, chronic illness, and genetic factors all increase the odds of a poor response. The nature of the vaccine itself also plays a role, including the dose and the type of immune-boosting ingredient (adjuvant) it contains.⁷

Genetics seem to play an underappreciated part. Early research identified a link between certain immune system gene variants (specifically in the HLA-DR region) and non-response to hepatitis B vaccination. People carrying one particular variant, HLA-DR3, were significantly more likely to fail the vaccine.⁸ This means that for some non-responders, the issue is hardwired and a different vaccine formulation or higher dose may be the only way to coax a response. Newer adjuvanted vaccines have shown particular promise in converting previous non-responders into responders, which is one reason the two-dose Heplisav-B has gained traction in recent years.

Healthcare Workers and Why Documentation Matters

If you work in healthcare, your employer almost certainly requires proof of hepatitis B immunity. This is not just a bureaucratic formality. Knowing your immune status changes what happens after a potential exposure. If you get stuck with a contaminated needle and your records show a documented titer above 10, you generally do not need post-exposure treatment. If your status is unknown or your titer was never checked, you may need hepatitis B immune globulin and possibly a vaccine booster on top of it.⁹

Many healthcare workers were vaccinated as children and never had a titer checked. If you were vaccinated more than a decade ago and never confirmed your response, your current anti-HBs level may well be undetectable. That does not necessarily mean you are unprotected. It does mean you lack documentation, and from an occupational health standpoint, the distinction between “protected but undocumented” and “unprotected” is not one most hospital systems are willing to split hairs over. Getting a titer drawn and recorded is the simplest way to avoid a complicated protocol after an exposure event.

Waning Titers Do Not Always Mean Lost Protection

One of the most common misconceptions about hepatitis B titers is that a low or undetectable antibody level years after vaccination means you are no longer immune. In reality, the immune system has a longer memory than a single blood test can capture. Research following vaccinated healthcare workers found that even when antibody titers dropped below 10 mIU/mL over the years, immunologic memory in B cells was still intact as far out as eight years after vaccination. Many experts believe protection lasts at least a decade, and possibly much longer, even in people whose titers have become undetectable.¹⁰

A booster dose can help prove this. In a 22-year follow-up study, participants who had responded to the original vaccine series were given a single booster dose. About 77% showed a strong anamnestic response (their immune system rapidly produced antibodies) within just 10 to 14 days, and 81% had reached protective levels by 60 days. The speed of that response is itself evidence of immune memory: someone who had never been vaccinated would not produce antibodies that fast.¹¹ Younger age and a higher peak antibody level after the original series both predicted a stronger booster response.

This is why the CDC does not currently recommend routine booster doses for healthy people who responded to the original series. The one-to-two-month post-vaccination titer confirms you responded. After that, in most cases, you can trust your immune memory to do its job even as circulating antibody levels naturally decline.

Accelerated Vaccine Schedules and When to Test

The standard hepatitis B schedule spaces three doses over six months (0, 1, and 6 months). But sometimes that timeline is too slow. Travelers heading to high-risk areas, people who inject drugs, or anyone at imminent risk of exposure may receive an accelerated schedule, which compresses the doses into a shorter period. One well-studied accelerated schedule delivers three doses over just three weeks (days 0, 7, and 21), with a booster at 12 months.

Accelerated schedules do work, but the antibody response tends to be lower. In a trial comparing the three-week schedule to the standard one, 70% of accelerated-group participants were seroprotected one month after the third dose, compared to 92% in the standard group. By the time booster doses were given, both groups converged, with about 93-95% showing protection.¹² A more recent study among people who inject drugs confirmed the same pattern: seroconversion was 99.5% in the standard group versus about 92% in the accelerated group, and the median antibody titer was roughly ten times higher with the standard schedule.¹³

If you are on an accelerated schedule, the one-to-two-month rule still applies: test one to two months after whatever dose is the final one in your series (not counting a later booster). Just be aware that a lower initial titer is expected and does not necessarily indicate vaccine failure. If the booster at 12 months is part of the protocol, some clinicians prefer to check the titer after that booster rather than after the compressed initial series, since the post-booster numbers are more representative of your long-term immunity.

Lab Tests Are Not All Created Equal

Something that rarely comes up in routine clinical conversations is that different laboratory assays for anti-HBs can give meaningfully different results on the same blood sample. A quality assessment study found that sensitivity ranged from 64% to 100% depending on the assay used, and agreement between assays around the critical 10 mIU/mL cutoff was generally good (93-100%). But at the 100 mIU/mL cutoff, which some guidelines use to distinguish moderate from strong responders, agreement between assays collapsed to just 44%.¹⁴

For most people, this variability does not change anything practical. If your titer is well above 10, every assay will agree you are protected. If your titer is well below 10, every assay will agree you are not. The gray zone is right around the cutoff. If your result comes back as something like 8 or 12 mIU/mL, the true value could plausibly be on either side of 10 depending on which test kit the lab used. This is one more reason the testing window matters: by drawing blood at peak antibody levels (one to two months out), you are more likely to get a clear, unambiguous result that does not leave you and your doctor guessing about a borderline number.

If you do get a borderline result and your clinician is uncertain, a reasonable approach is to repeat the test in a few weeks or simply start a second vaccine series rather than agonizing over a number that two different labs might interpret differently. The clinical stakes of one unnecessary vaccine dose are essentially zero, while the stakes of assuming you are immune when you are not can be serious for someone in a high-risk occupation or living situation.